In vitro and in vivo studies have suggested therapeutic applications of retinoic acid (RA) for treatment of human neuroblastoma. These studies have indicated that a limitation of treatment may be the outgrowth of neuroblastoma cells that are resistant to the differentiating action of RA. Based upon our in vitro findings that RA-resistant cell variants can be induced into a state of """"""""RA-responsiveness"""""""" by increasing intracellular levels of cAMP, we hypothesize that the clinical benefits of RA can be markedly enchanced by combining treatment with modalities that increase intratumor cAMP levels. This hypothesis will be directly tested by evaluating the development and growth of RA-sensitive and RA-resistant neuroblastoma cells in nude mice undergoing various treatment protocols with RA and cAMP-elevating agents. Our previous work has led us to hypothesize a role for modulation of voltage-gated Ca2+ channels by RA inducing differenitation of human neuroblastoma cells. Specific experimental aims for this period are designed to test this hypothesis. In doing so we will address two fundamental questions: Does RA modulate voltage- gated ion channels in human neuroblastoma cells? Is the ability of RA to alter ion channels involved in its differentiation-inducing activity? These investigations will employ the whole cell patch- clamp technique for the electrophysiologic membrane studies and compare the biologic activity of various retinoid derivatives and other """"""""classical"""""""" modulators with their effects on channel function. Information gained in this study should provide basic knowledge concerning the roles for ion channels and membrane ion fluxes in regulating cellular growth and differentiation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA043503-03
Application #
3185699
Study Section
Neurology C Study Section (NEUC)
Project Start
1986-05-01
Project End
1991-04-30
Budget Start
1988-05-01
Budget End
1989-04-30
Support Year
3
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Barua, Arun B; Sidell, Neil (2004) Retinoyl beta-glucuronide: a biologically active interesting retinoid. J Nutr 134:286S-289S
Tuthill, Matthew C; Wada, Randal K; Arimoto, Jason M et al. (2003) N-myc oncogene expression in neuroblastoma is driven by Sp1 and Sp3. Mol Genet Metab 80:272-80
Sidell, N; Pasquali, M; Malkapuram, S et al. (2003) In vitro and in vivo effects of easily administered, low-toxic retinoid and phenylacetate compounds on human neuroblastoma cells. Br J Cancer 89:412-9
Han, S; Wada, R K; Sidell, N (2001) Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. Cancer Res 61:3998-4002
Sawatsri, S; Samid, D; Malkapuram, S et al. (2001) Inhibition of estrogen-dependent breast cell responses with phenylacetate. Int J Cancer 93:687-92
Han, S W; Greene, M E; Pitts, J et al. (2001) Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin Cancer Res 7:98-104
Sidell, N; Sawatsri, S; Connor, M J et al. (2000) Pharmacokinetics of chronically administered all-trans-retinoyl-beta-glucuronide in mice. Biochim Biophys Acta 1502:264-72
Sidell, N; Chang, B; Yamashiro, J M et al. (1998) Transcriptional upregulation of retinoic acid receptor beta (RAR beta) expression by phenylacetate in human neuroblastoma cells. Exp Cell Res 239:169-74
Connor, M J; Sidell, N (1997) Retinoic acid synthesis in normal and Alzheimer diseased brain and human neural cells. Mol Chem Neuropathol 30:239-52
Wada, R K; Pai, D S; Huang, J et al. (1997) Interferon-gamma and retinoic acid down-regulate N-myc in neuroblastoma through complementary mechanisms of action. Cancer Lett 121:181-8

Showing the most recent 10 out of 33 publications